First Tracks Biotherapeutics, Inc.
TRAX
$15.97
$0.221.40%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.86M | 9.82M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 52.81M | 51.28M | |||
| Operating Income | -52.81M | -51.28M | |||
| Income Before Tax | -50.48M | -47.20M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.48M | -47.20M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.48M | -47.20M | |||
| EBIT | -52.81M | -51.28M | |||
| EBITDA | -52.69M | -51.13M | |||
| EPS Basic | -1.45 | -- | |||
| Normalized Basic EPS | -0.90 | -- | |||
| EPS Diluted | -1.45 | -- | |||
| Normalized Diluted EPS | -0.90 | -- | |||
| Average Basic Shares Outstanding | 34.89M | -- | |||
| Average Diluted Shares Outstanding | 34.89M | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||